Edesa Price To Sales Ratio vs Free Cash Flow Yield Analysis

EDSA Stock

USD 1.78 0.12 6.32%

Edesa Biotech financial indicator trend analysis is much more than just examining Edesa Biotech latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Edesa Biotech is a good investment. Please check the relationship between Edesa Biotech Price To Sales Ratio and its Free Cash Flow Yield accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Edesa Biotech Price To Sales Ratio account and Free Cash Flow Yield. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Edesa Biotech's Price To Sales Ratio and Free Cash Flow Yield is -0.23. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Edesa Biotech, assuming nothing else is changed. The correlation between historical values of Edesa Biotech's Price To Sales Ratio and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Edesa Biotech are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Price To Sales Ratio i.e., Edesa Biotech's Price To Sales Ratio and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.23

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Edesa Biotech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Edesa Biotech sales, a figure that is much harder to manipulate than other Edesa Biotech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Edesa Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Edesa Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.At present, Edesa Biotech's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 1 B, whereas Selling General Administrative is forecasted to decline to about 3.6 M.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	118.2K	183.5K	165.1K	156.9K
Research Development	13.3M	4.8M	5.5M	4.3M

Cost Of Revenue Research Development

Edesa Biotech fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Property Plant And Equipment Net	Net Receivables	Property Plant And Equipment Gross	Current Deferred Revenue	Non Current Liabilities Total	Intangible Assets	Common Stock Total Equity	Inventory	Common Stock	Short Term Investments	Other Assets
Total Assets		0.23	0.35	0.75	-0.8	-0.59	0.81	0.41	-0.02	0.89	0.23	0.51	0.1	0.26	0.97	0.21	0.32	0.24	-0.38	0.19	0.73	0.44	-0.14	0.6	0.45	0.14
Other Current Liab	0.23		0.8	-0.29	-0.29	-0.27	0.31	0.0	0.08	0.28	0.12	-0.13	0.46	0.73	0.27	-0.1	0.05	-0.1	0.57	0.59	-0.23	-0.09	-0.02	0.02	-0.18	-0.28
Total Current Liabilities	0.35	0.8		-0.21	-0.4	-0.24	0.43	0.25	0.2	0.27	0.26	0.06	0.52	0.79	0.31	-0.33	0.13	-0.32	0.26	0.6	-0.09	-0.3	-0.21	-0.02	0.09	-0.11
Total Stockholder Equity	0.75	-0.29	-0.21		-0.34	-0.57	0.36	0.44	0.07	0.58	0.28	0.59	-0.05	-0.44	0.69	0.32	0.39	0.35	-0.56	-0.48	0.86	0.56	-0.24	0.75	0.66	0.19
Net Debt	-0.8	-0.29	-0.4	-0.34		0.28	-0.99	-0.14	0.09	-0.82	-0.04	-0.31	-0.07	-0.59	-0.83	0.0	-0.14	0.0	0.21	-0.59	-0.45	-0.17	-0.02	-0.19	-0.04	-0.16
Retained Earnings	-0.59	-0.27	-0.24	-0.57	0.28		-0.32	-0.49	-0.47	-0.53	-0.47	-0.01	-0.45	0.02	-0.53	-0.36	-0.02	-0.41	0.11	0.17	-0.54	-0.57	0.32	-0.93	-0.38	0.49
Cash	0.81	0.31	0.43	0.36	-0.99	-0.32		0.21	-0.01	0.81	0.13	0.32	0.14	0.59	0.83	-0.04	0.15	-0.04	-0.17	0.57	0.47	0.15	-0.04	0.23	0.08	0.15
Non Current Assets Total	0.41	0.0	0.25	0.44	-0.14	-0.49	0.21		0.62	0.05	0.89	0.55	0.58	-0.09	0.21	-0.36	0.47	-0.33	-0.19	-0.27	0.39	-0.15	-0.81	0.45	0.64	0.17
Non Currrent Assets Other	-0.02	0.08	0.2	0.07	0.09	-0.47	-0.01	0.62		-0.19	0.88	0.04	0.78	-0.13	-0.14	-0.51	0.12	-0.48	0.15	-0.31	0.14	-0.3	-0.76	0.35	0.41	-0.26
Cash And Short Term Investments	0.89	0.28	0.27	0.58	-0.82	-0.53	0.81	0.05	-0.19		-0.07	0.14	-0.06	0.37	0.96	0.45	-0.05	0.45	-0.24	0.36	0.62	0.64	0.25	0.51	0.16	-0.05
Common Stock Shares Outstanding	0.23	0.12	0.26	0.28	-0.04	-0.47	0.13	0.89	0.88	-0.07		0.4	0.75	-0.1	0.06	-0.54	0.4	-0.5	0.06	-0.3	0.29	-0.31	-0.89	0.39	0.6	0.04
Other Current Assets	0.51	-0.13	0.06	0.59	-0.31	-0.01	0.32	0.55	0.04	0.14	0.4		0.05	-0.17	0.39	-0.34	0.84	-0.32	-0.5	-0.25	0.43	-0.21	-0.58	0.1	0.59	0.69
Other Stockholder Equity	0.1	0.46	0.52	-0.05	-0.07	-0.45	0.14	0.58	0.78	-0.06	0.75	0.05		0.21	0.0	-0.47	0.16	-0.44	0.42	0.0	-0.11	-0.34	-0.63	0.25	0.14	-0.39
Total Liab	0.26	0.73	0.79	-0.44	-0.59	0.02	0.59	-0.09	-0.13	0.37	-0.1	-0.17	0.21		0.31	-0.18	-0.13	-0.19	0.31	0.96	-0.27	-0.21	0.17	-0.28	-0.35	-0.08
Total Current Assets	0.97	0.27	0.31	0.69	-0.83	-0.53	0.83	0.21	-0.14	0.96	0.06	0.39	0.0	0.31		0.31	0.22	0.33	-0.33	0.27	0.67	0.53	0.05	0.53	0.31	0.09
Property Plant And Equipment Net	0.21	-0.1	-0.33	0.32	0.0	-0.36	-0.04	-0.36	-0.51	0.45	-0.54	-0.34	-0.47	-0.18	0.31		-0.42	1.0	-0.25	-0.07	0.24	0.91	0.61	0.46	-0.13	-0.33
Net Receivables	0.32	0.05	0.13	0.39	-0.14	-0.02	0.15	0.47	0.12	-0.05	0.4	0.84	0.16	-0.13	0.22	-0.42		-0.4	-0.23	-0.22	0.13	-0.32	-0.66	0.09	0.36	0.42
Property Plant And Equipment Gross	0.24	-0.1	-0.32	0.35	0.0	-0.41	-0.04	-0.33	-0.48	0.45	-0.5	-0.32	-0.44	-0.19	0.33	1.0	-0.4		-0.26	-0.09	0.26	0.92	0.58	0.5	-0.11	-0.34
Current Deferred Revenue	-0.38	0.57	0.26	-0.56	0.21	0.11	-0.17	-0.19	0.15	-0.24	0.06	-0.5	0.42	0.31	-0.33	-0.25	-0.23	-0.26		0.27	-0.52	-0.27	0.14	-0.21	-0.47	-0.46
Non Current Liabilities Total	0.19	0.59	0.6	-0.48	-0.59	0.17	0.57	-0.27	-0.31	0.36	-0.3	-0.25	0.0	0.96	0.27	-0.07	-0.22	-0.09	0.27		-0.32	-0.15	0.35	-0.37	-0.5	-0.04
Intangible Assets	0.73	-0.23	-0.09	0.86	-0.45	-0.54	0.47	0.39	0.14	0.62	0.29	0.43	-0.11	-0.27	0.67	0.24	0.13	0.26	-0.52	-0.32		0.49	-0.15	0.66	0.71	0.29
Common Stock Total Equity	0.44	-0.09	-0.3	0.56	-0.17	-0.57	0.15	-0.15	-0.3	0.64	-0.31	-0.21	-0.34	-0.21	0.53	0.91	-0.32	0.92	-0.27	-0.15	0.49		0.46	0.67	0.02	-0.35
Inventory	-0.14	-0.02	-0.21	-0.24	-0.02	0.32	-0.04	-0.81	-0.76	0.25	-0.89	-0.58	-0.63	0.17	0.05	0.61	-0.66	0.58	0.14	0.35	-0.15	0.46		-0.25	-0.55	-0.17
Common Stock	0.6	0.02	-0.02	0.75	-0.19	-0.93	0.23	0.45	0.35	0.51	0.39	0.1	0.25	-0.28	0.53	0.46	0.09	0.5	-0.21	-0.37	0.66	0.67	-0.25		0.46	-0.4
Short Term Investments	0.45	-0.18	0.09	0.66	-0.04	-0.38	0.08	0.64	0.41	0.16	0.6	0.59	0.14	-0.35	0.31	-0.13	0.36	-0.11	-0.47	-0.5	0.71	0.02	-0.55	0.46		0.42
Other Assets	0.14	-0.28	-0.11	0.19	-0.16	0.49	0.15	0.17	-0.26	-0.05	0.04	0.69	-0.39	-0.08	0.09	-0.33	0.42	-0.34	-0.46	-0.04	0.29	-0.35	-0.17	-0.4	0.42

Click cells to compare fundamentals

Edesa Biotech Account Relationship Matchups

Edesa Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.8M	14.6M	11.6M	8.9M	10.2M	8.7M
Other Current Liab	(69.7K)	1.4M	(19.0K)	1.7M	1.6M	1.7M
Total Current Liabilities	1.5M	1.5M	2.1M	1.8M	2.1M	1.3M
Total Stockholder Equity	6.6M	13.1M	9.4M	7.0M	8.1M	6.4M
Net Debt	(7.0M)	(7.7M)	(7.1M)	(5.3M)	(4.7M)	(5.0M)
Retained Earnings	(13.1M)	(26.5M)	(44.0M)	(52.4M)	(47.2M)	(44.8M)
Cash	7.2M	7.8M	7.1M	5.4M	6.2M	5.6M
Non Current Assets Total	2.7M	2.5M	2.5M	2.5M	2.8M	3.0M
Cash And Short Term Investments	7.2M	7.8M	7.1M	5.4M	6.2M	6.8M
Common Stock Shares Outstanding	1.2M	1.7M	2.1M	2.9M	3.3M	3.5M
Liabilities And Stockholders Equity	10.8M	14.6M	11.6M	8.9M	10.2M	8.7M
Other Current Assets	802.9K	1.9M	745.5K	448.9K	516.2K	402.8K
Other Stockholder Equity	1.6M	4.9M	11.2M	13.0M	15.0M	15.7M
Total Liab	4.1M	1.5M	2.2M	1.8M	2.1M	2.3M
Total Current Assets	8.1M	12.1M	9.1M	6.4M	7.4M	7.6M
Property Plant And Equipment Net	174.8K	111.6K	31.2K	100.1K	90.1K	85.6K
Net Receivables	87.4K	3.3M	1.3M	626.5K	720.5K	521.2K
Property Plant And Equipment Gross	174.8K	145.4K	70.7K	143.9K	129.5K	123.1K
Accumulated Other Comprehensive Income	(287.2K)	(205.3K)	(213.6K)	(214.6K)	(246.8K)	(234.5K)
Non Current Liabilities Total	2.6M	67.7K	43.7K	19.8K	17.8K	16.9K
Inventory	224.3K	(217.1K)	(87.4K)	(1.3M)	(1.1M)	(1.1M)
Common Stock	18.5M	34.9M	42.5M	46.6M	53.6M	39.4M
Property Plant Equipment	73.1K	174.8K	111.6K	31.2K	28.0K	26.6K
Accounts Payable	1.5M	1.4M	2.1M	1.7M	2.0M	1.2M
Net Tangible Assets	5.3M	4.1M	10.7M	7.1M	8.2M	4.3M
Net Invested Capital	6.6M	13.1M	9.4M	7.0M	8.1M	9.4M
Net Working Capital	6.6M	10.6M	7.0M	4.6M	4.2M	5.8M
Capital Stock	18.5M	34.9M	42.5M	46.6M	53.6M	38.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:

How To Invest In Edesa

Details

Is Edesa Stock a good investment?

Details

What is Edesa Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(19.78)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.72)

Return On Equity

(1.29)

The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Edesa Price To Sales Ratio vs Free Cash Flow Yield Analysis

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Free Cash Flow Yield

Edesa Biotech fundamental ratios Correlations

Edesa Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Edesa Biotech fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.97	Total Assets
Total Current Assets	+ 0.96	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.96	Total Liab
Common Stock Total Equity	+ 0.92	Property Plant And Equipment Gross
Common Stock Total Equity	+ 0.91	Property Plant And Equipment Net

Cash	- 0.99	Net Debt
Common Stock	- 0.93	Retained Earnings
Inventory	- 0.89	Common Stock Shares Outstanding
Total Current Assets	- 0.83	Net Debt
Cash And Short Term Investments	- 0.82	Net Debt
Inventory	- 0.81	Non Current Assets Total